CA3067398A1 - A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response - Google Patents

A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response Download PDF

Info

Publication number
CA3067398A1
CA3067398A1 CA3067398A CA3067398A CA3067398A1 CA 3067398 A1 CA3067398 A1 CA 3067398A1 CA 3067398 A CA3067398 A CA 3067398A CA 3067398 A CA3067398 A CA 3067398A CA 3067398 A1 CA3067398 A1 CA 3067398A1
Authority
CA
Canada
Prior art keywords
pain
compound
kappa
foregoing
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067398A
Other languages
English (en)
French (fr)
Inventor
Craig HARTRICK
Original Assignee
Caventure Drug Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caventure Drug Discovery Inc filed Critical Caventure Drug Discovery Inc
Publication of CA3067398A1 publication Critical patent/CA3067398A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dowels (AREA)
CA3067398A 2017-07-06 2018-06-22 A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response Pending CA3067398A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529285P 2017-07-06 2017-07-06
US62/529,285 2017-07-06
PCT/US2018/038936 WO2019010014A1 (en) 2017-07-06 2018-06-22 OPIOID KAPPA AND DELTA AGONIST WITH DOUBLE ACTION LIMITED TO PERIPHERY FOR ANALGESIA IN PAIN CONDITIONS INVOLVING INFLAMMATORY RESPONSE

Publications (1)

Publication Number Publication Date
CA3067398A1 true CA3067398A1 (en) 2019-01-10

Family

ID=64950308

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067398A Pending CA3067398A1 (en) 2017-07-06 2018-06-22 A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response

Country Status (10)

Country Link
US (2) US11185551B2 (enExample)
EP (1) EP3649132B1 (enExample)
JP (1) JP7233741B2 (enExample)
KR (1) KR20200026962A (enExample)
CN (2) CN111278831A (enExample)
AU (1) AU2018297214B2 (enExample)
CA (1) CA3067398A1 (enExample)
IL (1) IL271772A (enExample)
SG (1) SG11201912036XA (enExample)
WO (1) WO2019010014A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222543A1 (en) * 2021-06-07 2022-12-15 Uwm Research Foundation, Inc. Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
US20030008807A1 (en) * 2001-06-14 2003-01-09 The Regents Of The University Of California Novel signaling pathway for the production of inflammatory pain and neuropathy
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
WO2015114660A1 (en) 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists

Also Published As

Publication number Publication date
JP7233741B2 (ja) 2023-03-07
EP3649132B1 (en) 2023-12-27
CN111278831A (zh) 2020-06-12
SG11201912036XA (en) 2020-01-30
EP3649132A1 (en) 2020-05-13
US20210161912A1 (en) 2021-06-03
AU2018297214A1 (en) 2020-01-16
EP3649132A4 (en) 2021-04-07
US20220288089A1 (en) 2022-09-15
IL271772A (en) 2020-02-27
AU2018297214B2 (en) 2022-09-01
WO2019010014A1 (en) 2019-01-10
JP2020525548A (ja) 2020-08-27
CN116440140A (zh) 2023-07-18
US11185551B2 (en) 2021-11-30
KR20200026962A (ko) 2020-03-11

Similar Documents

Publication Publication Date Title
Rastogi et al. Novel treatment modalities for painful diabetic neuropathy
EP2813224A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
AU2021204517B2 (en) Combination of opioids and n-acylethanolamines
CN113557022A (zh) 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
US20220288089A1 (en) Peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response
US20240197756A1 (en) Methods of treatment with neuroactive steroids
CN115279197A (zh) 增强型含咖啡因饮料组合物
CN108697758B (zh) 用于有效控制急性和/或慢性疼痛的药物及其施用方法
HK40093852A (en) Combinations of opioids and n-acylethanolamines
Zhao et al. Synergistic antinociceptive interactions between fospropofol and alfentanil in mice
Tillisch et al. T1261 The Effect of Chronic Neurokinin-1 Receptor Antagonism On Sympathetic Nervous System Activity in Irritable Bowel Syndrome (IBS)
Kitazawa et al. T1260 Ghrelin Stimulates Gastric Motility Through Activation of the Vago-Vagal Reflex Pathway in the Anesthetized Guinea-Pig
Yu et al. T1262 Methylnaltrexone for Treatment of Postoperative Ileus: Combined Safety Analysis from Two Phase 3 Studies
EA040799B1 (ru) Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230526

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241008

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250611

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250611

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804